IGF1R and Hyperglycemia: On the one hand, blocking both IGF1R and IR can result in dose-limiting hyperglycaemia,46,47 but, on the other hand, exclusively inhibiting IGF1R can cause compensatory activation of IR signalling.48,49 Investigation of various targets are ongoing, but for the purposes of this review, we will highlight some that are the most advanced in clinical development.